TransCode Therapeutics Reported Earnings

TransCode Therapeutics (RNAZ) reported a loss of $7.17 per share on revenue of $0.00 million for the . .

TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.